

DMICC

DIABETES MELLITUS INTERAGENCY COORDINATING COMMITTEE (DMICC) Psychoactive Drugs and Type 2 Diabetes

Bethesda Marriott Suites

8:30 a.m. – 3:30 p.m.

September 18, 2006

AGENDA

8:30 – 8:40 a.m. Welcome and Introductions Judy Fradkin and Griff Rodgers
National Institute of Diabetes and Digestive
and Kidney Diseases

SESSION I: OVERVIEW OF THE PROBLEM

8:40 – 8:45 a.m. Moderator Mark Chavez
National Institute of Mental Health

8:45 – 9:30 a.m. Disorders, Drugs, Metabolic Outcomes John Newcomer
Washington University in St. Louis

9:30 – 10:00 a.m. Discussant Samuel Dagogo-Jack
University of Tennessee, Memphis

Discussion points, including areas of consensus and contention:

- (1) Mechanisms of direct drug effects on insulin sensitivity and insulin secretion, independent of effects on adiposity (e.g., drug effects on glucose transporter function and insulin signaling pathways).
- (2) Although most current data concern adverse effects of antipsychotics, there is evidence of substantial effects of certain mood stabilizers and antidepressants on weight. What are the effects of these medications on metabolic endpoints?
- (3) What is the extent of background diabetes risk in psychotic disorders?
- (4) Management of Antipsychotic-Associated Diabetes.

10:00 – 10:15 a.m. BREAK

SESSION II: PSYCHOACTIVE DRUGS AND THEIR METABOLIC OUTCOMES

10:15 – 10:20 a.m. Moderator	Sanford Garfield National Institute of Diabetes and Digestive and Kidney Diseases
10:20 – 10:55 a.m. Mechanisms and Pathogenesis	Richard Bergman Keck School of Medicine
10:55 – 11:30 a.m.	Marilyn Ader Keck School of Medicine
11:30 – 12:00 noon Discussant	John Newcomer Washington University in St. Louis

Discussion points, including areas of consensus and contention:

- (1) Are there effects of drugs to increase diabetes risk that are independent of drug effects on body weight and/or body fat?
- (2) Are the metabolic effects of antipsychotics mediated by central or peripheral mechanisms?
- (3) How can the DMICC facilitate the clinical research interaction between psychiatrists and basic researchers with expertise in diabetes pathogenesis and obesity?

12:00 noon – 1:00 p.m. LUNCH (on your own)

SESSION III: PREVENTION AND TREATMENT

1:00 – 1:05 p.m. Moderator	Michael J. Sernyak Yale University School of Medicine
1:05 – 1:50 p.m. Drugs and Lifestyle Intervention	Tony Cohn University of Toronto
1:50 – 2:30 p.m. Discussant	Michael J. Sernyak Yale University School of Medicine

Discussion points, including areas of consensus and contention:

- (1) How should diabetes prevention/treatment strategies be applied to the psychiatric population? What are the specific challenges/opportunities? Are standard medication/behavioral approaches effective?
- (2) How can lifestyle interventions be integrated into mental health care?
- (3) Does use of expert guidelines for monitoring patients taking antipsychotics (e.g., Mt. Sinai recommendations, ADA/APA recommendations) improve patient outcomes (e.g., diabetes prevention, prevention of weight gain)?

(4) What lifestyle interventions to prevent or reduce weight gain and prevent diabetes mellitus are practical, effective, and can be delivered in a variety of mental health consumer settings?

SESSION IV: PANEL DISCUSSION: KEY UNANSWERED QUESTIONS AND COMPELLING RESEARCH OPPORTUNITIES

2:30 – 3:30 p.m. Moderator

Judy Fradkin
National Institute of Diabetes and Digestive
and Kidney Diseases

Panel Members: (5 minutes for each panel member, then discussion)

Michael J. Sernyak, Yale University School of Medicine

Rohan Ganguli, University of Pittsburg

Gail Daumit, Johns Hopkins University

Richard Kahn, American Diabetes Association

Mary Parks, U.S. Food and Drug Administration

3:30 p.m. Closing Remarks and Adjournment

Judy Fradkin
National Institute of Diabetes and Digestive
and Kidney Diseases